MINNEAPOLIS, May 14, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the market leading medical device company for BPH in-office procedures, announced scheduled participation in multiple events at the American Urological Association (AUA) 2012 Annual Meeting to be held at the Georgia World Congress Center in Atlanta from May 19th through May 23rd. The Company's event participation is intended to sharpen the focus on advancements in the in-office treatment of BPH. Urologix offers early and effective treatment of obstructive and symptomatic urinary conditions due to benign prostatic hyperplasia (BPH) and provides urologists with two proven technologies to treat the widest range of patients, with Cooled ThermoTherapy™ and Prostiva® RF Therapy.
Urologix will sponsor a one-hour expert panel lecture titled "Fact, Not Fiction: The Truth about In-Office BPH Treatments" on Tuesday, May 22nd. This discussion will be moderated by Dr. Claus Roehrborn from the University of Texas Southwestern Medical Center in Dallas and participants will include three experienced urology practitioners of in-office BPH therapies – Drs. Mark Fallen, Robert Pugach, and John Harb. Panel discussion subjects will include patient selection, patient comfort, and a comparison of treatment efficacy, durability, and cost-effectiveness.
Additionally, Dr. Lori Lerner is presenting a poster on CTT on Sunday, May 20th. Dr. Lerner is coauthor of the accepted abstract: "Medication vs. Microwave: A Comparison of Nocturia, Quality of Life and Cost" and her presentation topics include clinical outcomes for improving Nocturia using Urologix's Cooled ThermoTherapy™ (CTT) product.
Finally, Urologix will be an exhibitor and sponsor of an In-Office BPH Therapies Skills Enhancement Workshop at the 2012 AUA Annual Meeting. The Workshop will be staffed by experienced urologists who will offer in-depth discussions with attendees on both the advancements in, and the clinical experiences with, in-office BPH therapies – specifically, the Cooled ThermoTherapy™ and Prostiva® RF Therapy technologies. The workshop will include the most recent clinical data, educational videos, and product demonstrations.
"We are excited to introduce the 'New' Urologix, demonstrating our commitment as the market leader for in-office BPH therapy at the 2012 AUA Annual Meeting," commented Stryker Warren jr., Chief Executive Officer of Urologix. "Most importantly, we look forward to providing evidence, to enable urologists to see Cooled ThermoTherapy™ and Prostiva® RF Therapy as safe and durable treatment options for their BPH patients failing or unhappy with drug therapy, or those seeking a non-surgical alternative."
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
The Urologix, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7867
CONTACT: Urologix: Stryker Warren jr., CEO (763) 475-1400